Eli Lilly and Co
(BSP:LILY34)
R$
154
-1.68 (-1.08%)
Market Cap: 4.43 Tn
Enterprise Value: 4.59 Tn
PE Ratio: 86.21
PB Ratio: 50.39
GF Score: 77/100 Eli Lilly and Co at UBS BioPharma Conference Transcript
Nov 08, 2023 / 08:00PM GMT
Release Date Price:
R$102.16
(+4.19%)
Trung Chuong Huynh
UBS Investment Bank, Research Division - Analyst
Okay. We're at the hour now. My name is Trung Huynh. I'm the U.S. pharma analyst here at UBS. Thank you, everyone, for joining in the room and also online. It's my pleasure today to host Eli Lilly, and we've got Patrik Jonsson, the President of Lilly Immunology. But upon Mike Mason's retirement, he's going to be -- his new title will be President of Lilly Diabetes and Obesity as well as the President of Lilly USA. So welcome, Patrik.
Patrik Jonsson
Eli Lilly and Company - EVP, Chief Customer Officer, President of Lilly Diabetes & Obesity and President Lilly USA
Thank you so much, Trung.
Questions & Answers
Trung Chuong Huynh
UBS Investment Bank, Research Division - Analyst
We've got Lilly on a momentous day today with the approval of Zepbound. So I appreciate there's going to be a lot of interest in diabetes and the obesity space, but I will be touching later on in immunology, which is Patrik's current day job at the moment.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot